Ivana Urošević

Ivana Urošević

Auto-generated profile, based on publicly available information

Ivana Urošević

Faculty of Medicine, Clinic of Hematology, University of Novi Sad, University Clinical Center of Vojvodina, Novi Sad, Serbia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
IUIvana Urosevic
Ivana Urosevic
MDMarina Dokic
Marina Dokic
IPIvanka Percic
Ivanka Percic
AFAmir El Farra
Amir El Farra
DBDunja Bjelogrlic
Dunja Bjelogrlic
BSBorivoj Sekulic
Borivoj Sekulic

10 March 2023 in Life
Verified
Journal Article
Open access
PDF file
DODusanka Obradovic
Dusanka Obradovic
MPMilica Popović
Milica Popović
MBMaja Banjac
Maja Banjac
JBJelena Bulajić
Jelena Bulajić
VĐVladimir Đurović
Vladimir Đurović
AMAleksandra Milovancev
Aleksandra Milovancev
Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow oxygen therapy. Methods. This retrospective study included hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive ventilation receiving standard of care (SOC) or SOC in addition to baricitinib. Data on patients’ characteristics, pro-inflammatory markers, D dimer, and National Early Warning Score 2 (NEWS2) values were collected and compared between groups. The primary endpoint was 28-day all-cause in-hospital mortality and the secondary outcome was transfer to the ICU. Results. The study included 125 patients. The primary outcome was observed in 44.8% of them: 27% in the baricitinib group vs. 62% in the SOC group, p < 0.001. Transfer to the ICU ward was significantly lower in the baricitinib group: 29% vs. 81%, p < 0.001. A significant improvement was observed when the baricitinib group was compared to SOC in procalcitonin, CRP, D-dimer, neutrophil-to-lymphocyte ratio values, and NEWS2. Conclusion. Treatment with baricitinib in addition to SOC was associated with reduced mortality and a lower prevalence of transfer to the ICU in hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive therapy.

8 May 2024 in Clinical Case Reports
Verified
Journal Article
Open access
JIJovanka Ilic
Jovanka Ilic
BPBorislava Pujic
Borislava Pujic
BJBranislava Jakovljevic
Branislava Jakovljevic
BSBorivoj Sekulic
Borivoj Sekulic
DADanijela Agic
Danijela Agic
ASAleksandar Savic
Aleksandar Savic
Key Clinical Message: Paroxysmal nocturnal hemoglobinuria is a rare disease with the incidence ranging from 0.08 to 0.57 per 100,000 person‐years. Up to 25% of cases in women are detected during pregnancy. We report two cases of successful pregnancy outcomes in patients treated with eculizumab, pointing out the importance of interdisciplinary approach in these high‐risk pregnancies.

1 January 2022 in Medicinski Pregled
Verified
Journal Article
Closed access
PDF file
IUIvana Urosevic
Ivana Urosevic
ABAndrija Bogdanovic
Andrija Bogdanovic
DLDanijela Leković
Danijela Leković
Introduction. The Myeloproliferative Neoplasms are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by increased proliferation of the myeloid lineages in the bone marrow. A particular clinical challenge is presented by certain situations in patients with myeloproliferative Neoplasms, which we do not encounter daily. For this reason, in this paper, we will emphasize the approach to overcoming obstacles in patients with Myeloproliferative Neoplasms in specific settings, like pregnancy. Pregnancy with Philadelphia chromosome-negative Myeloproliferative Neoplasms has been reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction leading to fetal growth restriction or loss. Thrombocytosis, leucocytosis, high level of hematocrit, activation of Platelets, leucocytes, and circulating pro-thrombotic are connected with the pathogenesis of thrombosis in MPNs With survival expectations similar to age-matched controls and excellent response and worldwide access to tyrosine kinase inhibitors, family planning is increasingly important for many patients with chronic myeloid leukemia. All patients were managed by a multidisciplinary team of physicians with obligatory hematological and gynecologistsobstetrician consultations.

1 January 2024 in Srpski medicinski casopis Lekarske komore
Verified
Journal Article
Open access
PDF file
NVNada V. Vlaisavljevic
Nada V. Vlaisavljevic
IUIvana Urošević
Ivana Urošević
DTDragana Tomić-Naglić
Dragana Tomić-Naglić
Introduction: According to the results of previous research, it was found that the dysfunction of the insulin-like growth factor (IGF) system, which is the basis of insulin resistance with hyperinsulinemia, acts as a proliferative tumor factor, and its neoplastic potential is also exhibited in multiple myeloma. Study aim: The study aims to determine whether there is an association between insulin resistance in patients newly diagnosed with multiple myeloma (NDMM) and the achieved therapeutic response after induction chemotherapy. Materials and methods: The prospective study included 35 NDMM patients (60% women and 40% men), treated at the Clinical Center of Vojvodina Clinic for Hematology. Glycemia and insulinemia levels were determined after fasting and postprandially, upon which the values of HOMA-IRIf (after fasting) and HOMA-IRIpp (postprandially) were calculated. HOMA-IRI values > 2.2 were the criteria for insulin resistance. The analyses were performed twice - before the initial chemotherapy and after the completion of the treatment. The therapeutic response was evaluated according to the criteria of the Serbian Myeloma Group (SMG) and the International Myeloma Working Group IMWG). Statistical analyses were performed in the SPSS program, Version 22. Results: The average patient age was 63.85 years. In total, 86% of patients responded favorably to the therapy. The average value of HOMA-IRIf before treatment was 1.82 ± 0.79 and it was 1.80 ± 0.72 after therapy. The central median value of HOMA-IRIpp before treatment was 5.46, with an interquartile range of 1.07 - 20.57, and after treatment, it was 5.86 with an interquartile range of 1.22 - 28.22. A significant negative correlation between HOMA-IRIf after applied treatment and achieved therapeutic response was observed, (p = 0.040). Conclusion: Active concomitant therapy of insulin resistance in NDMM could improve the response to applied antimyeloma treatment.

1 January 2024 in Srpski medicinski casopis Lekarske komore
Verified
Journal Article
Open access
PDF file
DADanijela Agić
Danijela Agić
MVMarijana Vranješ
Marijana Vranješ
MDMarina Dragičević-Jojkić
Marina Dragičević-Jojkić
FEFarra Amir El
Farra Amir El
IUIvana Urošević
Ivana Urošević
Introduction: Ferroptosis, mentioned as such for the first time in 2012 by Dixon et al., is an iron-dependent type of cell death that occurs in the presence of lipid peroxides. The mechanism of the process and the signaling pathways involved in it differ from the previously known apoptosis, necrosis, and autophagy. An inflammatory reaction also occurs, which further distinguishes this type of cell death from apoptosis. Ferrostatin inhibits this process. Methods: A review of the literature obtained by searching the Medline database was performed, with a special focus on studies concerned with the importance of ferroptosis in clinical medicine, primarily hematology. Results: Iron metabolism in malignant and healthy cells differs. Malignant cells tolerate oxidative stress well and avoid ferroptosis. According to literature data, various tested agents stimulate ferroptosis and thus become possible therapeutic agents. Some genes linked to iron metabolism have shown prognostic significance in patients with diffuse large B-cell lymphoma. Conclusion: The discovery of new mechanisms of cell death and the signaling pathways involved in this process leads to potentially new target therapy. Although promising, these results require validation through further research.